We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking "Accept," you agree to our website's cookie use as described in our Privacy Policy.
ACCEPTDenyPREFERENCES
+

Link to Healthcare Professionals Site

The information contained in this section is intended for U.S. healthcare professionals only.

Enter the SiteCancel
+

Find a Prescriber Near You

* Intended for US residents only
Thank you!

We will contact you promptly.
Oops! Something went wrong while submitting the form.

Provide a more enjoyable FDA-cleared treatment

In the Luminopia clinical trial, the rate of adherence to prescribed treatment was almost double the rate of adherence measured in patching clinical trials.3,6
Contact a Rep

86%

of children saw vision improvement with Luminopia

94%

of children saw vision improvement with Luminopia

85%

of children saw vision improvement with Luminopia
Contact a Rep

Our comfortable, lightweight VR headsets display the TV content which keeps patients engaged and distraction-free throughout treatment. By prescribing Luminopia, you’re giving patients the opportunity to watch TV for 1 hour a day, 6 days a week instead of wearing an eye patch.

Contact a Rep

Clinical Data

Proven efficacy and safety

3

US-based clinical trials

23

Sites

200+

Patients

Rapid and sustained vision improvement through 12 weeks

*p<0.05     **p<0.01
Primary endpoint at 12 weeks was met (p=0.001)
† Rapid” is defined as first follow-up at 4 weeks
Luminopia
Control (glasses alone)

Luminopia demonstrates significant vision improvement in previously treated patients

Graph of data depicting vision improvement with Luminopia among previously treated patients
*p<0.05     **p<0.01
‍
Luminopia
Control (glasses alone)
CHECK OUT THE CLINICAL RESEARCH

How Luminopia works

Unique, dual-acting binocular mechanism encourages both eyes to work together to improve vision

Reducing contrast

to the stronger eye overcomes suppression of the amblyopic eye4

Dichoptic masking

blocks complementary parts of the image for each eye to encourage the brain to combine the videos into one complete image5

See how easy it is to prescribe Luminopia in just a few minutes
Start Prescribing
Photo of doctor writing Luminopia prescription
Contact your local Luminopia Key Account Manager to demo our headset, answer questions, and onboard your practice
Fill the form

Luminopia is FDA cleared

  • Less Time Consuming

    Luminopia is only 1 hour a day, 6 days a week

  • Shorter Treatment Duration

    Luminopia has a shorter treatment duration than patching (1/3 of typical course of treatment)

  • Loved by Parents

    94% of caregivers prefer Luminopia over patching

  • Clinically Proven

    86% of children saw vision improvement with Luminopia

Phase 3 Trial Study Design
The phase 3 randomized trial vs glasses alone included 117 patients ages 4-7 with unilateral amblyopia associated with anisometropia and/or strabismus. The trial evaluated Luminopia 1 hour/day, 6 days/week with full-time corrective refraction vs full-time corrective refraction alone. The primary endpoint was change in BCVA at 12 weeks.1
Indication
Luminopia is indicated for improvement in visual acuity in amblyopia patients age 4-7, associated with anisometropia and/or with mild strabismus. Luminopia is intended to be used as an adjunct to full-time refractive correction, in an at-home environment, and is for Prescription Use Only.
Safety
  • No serious adverse events* reported with Luminopia
  • Most common adverse event reported (treatment v. control): Headaches (14.3% vs. 1.7%), all graded as mild and transient
  • Cases of new or worsening heterotropia were balanced between groups (7.1% vs. 8.5%)
  • Rate of all ocular adverse events similar between groups
*Includes events classified with possible, probably, or definite relation to study treatment
Important Information About Luminopia
  • Patients should only use Luminopia while wearing their prescribed refractive correction under the headset
  • Patients should wear Luminopia while seated or lying down
  • Additional evaluation may be required for patients with a history of light-induced seizures, serious medical conditions, new or worsening eye-turn, or double vision
  • Patients should stop using Luminopia and contact you for additional evaluation if they experience worsening vision in either eye, headache, nausea, eye strain that doesn't go away after usage, dizziness, or increased night terrors
Sources
  1. Luminopia. Directions for use, LBL-0001 Rev B. Luminopia, Inc.; 20224
  2. Xiao, S., Angjeli, E., Wu, H. C., Gaier, E. D., Gomez, S., Travers, D. A., Binenbaum, G., Langer, R., Hunter, D. G., Repka, M. X., & Luminopia Pivotal Trial Group (2022). Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia. Ophthalmology, 129(1), 77–85. https://doi.org/10.1016/j.ophtha.2021.09.001.
  3. Data on file, 2023. Luminopia, Inc.
  4. Li, J., Thompson, B., Lam, C. S., Deng, D., Chan, L. Y., Maehara, G., Woo, G. C., Yu, M., & Hess, R. F. (2011). The role of suppression in amblyopia. Investigative ophthalmology & visual science, 52(7), 4169–4176. https://doi.org/10.1167/iovs.11-7233
  5. Birch, E. E., Jost, R. M., Wang, Y. Z., Kelly, K. R., & Giaschi, D. E. (2019). Impaired Fellow Eye Motion Perception and Abnormal Binocular Function. Investigative ophthalmology & visual science, 60(10), 3374–3380. https://doi.org/10.1167/iovs.19-26885
  6. Wallace, M. P., Stewart, C. E., Moseley, M. J., Stephens, D. A., Fielder, A. R., Monitored Occlusion Treatment Amblyopia Study (MOTAS) Cooperatives, & Randomized Occlusion Treatment Amblyopia Study (ROTAS) Cooperatives (2013). Compliance with occlusion therapy for childhood amblyopia. Investigative ophthalmology & visual science, 54(9), 6158–6166. https://doi.org/10.1167/iovs.13-11861